{"classes":[{"categories":[{"measurements":[{"comment":"There were not enough events/deaths to compute a median or 95% confidence interval.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"There were not enough events/deaths to compute a median or 95% confidence interval.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"There were not enough events/deaths to compute a median or 95% confidence interval.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Overall survival is defined as the time from date of randomization to the date of death (due to any cause). For participants whose last known status is alive at the data cutoff date for the analysis, time will be censored as the last contact date prior to the data cutoff date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 8 mg/kg Ramucirumab administered as an intravenous infusion Q2W with 3 doses per 42 day cycle.","id":"OG000","title":"8 mg/kg Ramucirumab (Part A)"},{"description":"Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle.","id":"OG001","title":"12 mg/kg Ramucirumab (Part A)"},{"description":"Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle.","id":"OG002","title":"12 mg/kg Ramucirumab (Part B)"}],"paramType":"MEDIAN","populationDescription":"All randomized participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline to Date of Death from Any Cause (Up to 42 Months)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}